Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients With Cardiovascular Disease.

NCT04665830 is registered in ClinicalTrials.gov with Hamid Al-Essa Organ Transplant Center as lead sponsor.

NCT NCT04665830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients With Cardiovascular Disease.
Lead sponsor
Hamid Al-Essa Organ Transplant Center
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2018
Completion date
May 1, 2020
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kideny transplant recipients with high cardiovascular risk score